Efficacy and tolerability of pegylated IFN-α in patients with neuroendocrine gastroenteropancreatic carcinomas

Journal of Interferon and Cytokine Research

Volumn 26, Issue 1, 2006, Pages 8-13

  Pavel, Marianne E ^a,b   Baum, Ulrich ^a   Hahn, Eckhart G ^a   Schuppan, Detlef ^a   Lohmann, Tobias ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIVIRAL ACTIVITY; ARTICLE; CANCER INHIBITION; CHILL; CLINICAL ARTICLE; COLON TUMOR; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; ILEUM TUMOR; LEUKOPENIA; MALE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PARESTHESIA; PRIORITY JOURNAL; RECTUM TUMOR; THROMBOCYTOPENIA; TUMOR GROWTH; WEAKNESS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, NEUROENDOCRINE; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 32044457410     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.8     Document Type: Article

References (28)

1. De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R. EORTC (30885) randomised phase III study with recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma: the EORTC Genitourinary Group. Br. J. Cancer 1995;71:371-375.
2. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin. Hematol. 1997;24(Suppl. 4):S24-S31.
3. Baccarani M, Russo D, Rosti G, Martinelli G. Interferon-alfa for chronic myeloid leukemia. Semin. Hematol. 2003;40:22-33.
4. Öberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N. Engl. J. Med. 1983; 309:129-133.
5. Öberg K, Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991;30:519-522.
6. Eriksson B, Öberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol. 1993;32:203-208.
7. Öberg K. Interferon in the management of neuroendocrine GEP-tumors. Digestion 2000;62(Suppl. 1):92-97.
8. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B and International Lanreotide and Interferon Alfa Study Group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 2003;21:2689-2696.
9. Norioka K, Mitaka T, Mochizuki Y, Hara M, Kawagoe M, Nakamura H. Interaction of interleukin-1 and interferon-gamma on fibroblast growth factor-induced angiogenesis. Jpn. J. Cancer Res. 1994:85:522-529.
10. Vermeulen PB, Dirix LY, Martin M, Lemmens J, van Oosterom AT. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b. J. Natl. Cancer Inst. 1997;89:1316-1317.
11. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 1999;5:2726-2734.
12. Oliveira IC, Sciavolino PJ, Lee TH, Vilcek J. Down-regulation of interleukin-8 expression in human fibroblasts: unique mechanism of transcriptional inhibition of interferon. Proc. Natl. Acad. Sci. USA 1992;89:9049-9053.
13. Singh RK, Gutman M, Llansa N, Fidler IJ. Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma. J. Interferon Cytokine Res. 1996;16:577-584.
14. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Öberg K, Wiedenmann B, Hocker M, Rosewicz S. Effects of interferon-alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 2003;95:437-448.
15. van Damme J, Opdenakker G. Interaction of interferons with skin reactive cytokines: from interleukin 1 to interleukin 8. J. Invest. Dermatol. 1990;95:90-93.
16. Fabra A, Nakajima M, Bucana CD, Fidler IJ. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation 1992;52:101-110.
17. Gohji K, Fidler IJ, Tsan R, Radinsky R, von Eschenbach AC, Tsuruo T, Nakajima M. Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer 1994;58:380-384.
18. Öberg K, Eriksson B, Janson ET. Interferons alone or in combination with other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion 1994;55(Suppl. 3):64-69.
19. Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon alfa-2b: pharmacokinetic, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 2000;68:556-567.
20. Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr. Pharm. Des. 2002;8:2139-2157.
21. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, de Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000;343: 2673-2680.
22. Reddy RK, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP 3rd, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-438.
23. Bukowski RM, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J. Clin. Oncol. 2000;20:3841-3949.
24. Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG-intron. Cancer 2002; 95:389-396.
25. Bender H, Maier A, Wiedenmann B, O'Connor DT, Messner K, Schmidt-Gayk H. Immunoluminometric assay of chromogranin A in serum with commercially available reagents. Clin. Chem. 1992; 38:2267-2272.
26. Baker DE. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev. Gastroenterol. Disord. 2003;3:93-109.
27. Talpaz M, O'Brien S, Rose E, Gupta S, Shan J, Cortes J, Giles FJ, Faderl S, Kantarjian HM. Phase I study of polyethylene glycol formulation of interferon alpha-2B (Pegintron; Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukaemia. Blood 2001;98:1708-1713.
28. Bauer JA, Morrison BH, Grane RW, Jacobs BS, Borden EC, Lindner DJ. IFN-a2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J. Interferon Cytokine Res. 2003;23:3-10.